Abstract | INTRODUCTION:
Ovarian cancer ascitic fluid, which contains malignant cells, is usually present in women with an advanced stage disease. There are currently no effective therapies for the treatment of ovarian cancer ascitic fluid. We developed a new therapeutic strategy to target expression of the diphtheria toxin fragment A gene in ovarian tumor cells under the control of H19 regulatory sequences. CASE PRESENTATION: CONCLUSION: On the basis of this preliminary experience, we are currently conducting an extensive Phase I study on a larger number of patients in order to assess the safety and preliminary efficacy of this novel patient-oriented treatment approach.
|
Authors | Aya Mizrahi, Abraham Czerniak, Patricia Ohana, Smadar Amiur, Jennifer Gallula, Imad Matouk, Rasha Abu-Lail, Tatiana Birman, Abraham Hochberg, Tally Levy |
Journal | Journal of medical case reports
(J Med Case Rep)
Vol. 4
Pg. 228
(Jul 27 2010)
ISSN: 1752-1947 [Electronic] England |
PMID | 20663201
(Publication Type: Journal Article)
|